Covishield vs Covaxin: Which Vaccine is Better?
- As the world continues to grapple with the COVID-19 pandemic, two vaccines, Covishield and Covaxin, have emerged as crucial tools in India's fight against the virus.
- Covishield uses a weakened version of a common cold virus (adenovirus) from chimpanzees, modified to resemble the coronavirus.
- International clinical trials for Covishield indicated that a half dose followed by a full dose resulted in up to 90% effectiveness.However, unpublished data suggests that a longer interval...
Covishield and Covaxin: Which COVID-19 vaccine is better? News Directory 3 breaks down the critical differences between these front-line vaccines in India’s fight against the pandemic. You’ll discover Covishield employs a modified chimpanzee adenovirus, while Covaxin utilizes inactivated coronaviruses. Uncover disparate efficacy rates, from Covishield’s varied results to Covaxin’s notable 100% effectiveness against severe infection during trials.Understand the minor, shared side effects and the vast vaccination progress in India, exceeding 16.04 crore doses. This vital information arms you with knowledge. Discover what’s next for vaccine progress.
covishield vs. Covaxin: Understanding Key COVID-19 vaccine Differences
Updated May 30, 2025
As the world continues to grapple with the COVID-19 pandemic, two vaccines, Covishield and Covaxin, have emerged as crucial tools in India’s fight against the virus. Covishield, produced by the Serum Institute of India (SII) in collaboration with Oxford-AstraZeneca, and Covaxin, developed by Bharat Biotech in partnership with the Indian Council of Medical research (ICMR) and the National Institute of Virology (NIV), offer different approaches to immunization.
Covishield uses a weakened version of a common cold virus (adenovirus) from chimpanzees, modified to resemble the coronavirus. Once administered, it prompts the immune system to produce antibodies, preparing it to fight off any subsequent coronavirus infection. In contrast, covaxin is an inactivated vaccine, utilizing killed coronaviruses to safely trigger an immune response. Both vaccines aim to stimulate antibody production, providing protection against the virus.
Efficacy rates differ between the two. International clinical trials for Covishield indicated that a half dose followed by a full dose resulted in up to 90% effectiveness.However, unpublished data suggests that a longer interval between doses can boost its overall effectiveness. Bharat Biotech reported that interim analysis of Covaxin’s Phase III trial demonstrated 100% effectiveness against severe SARS-CoV-2 infection, leading to a reduction in hospitalizations. These findings underscore the importance of both vaccines in mitigating the pandemic’s impact.
Both Covishield and Covaxin are administered intramuscularly and have proven to be generally safe. Common side effects include pain and tenderness at the injection site, headache, and fatigue. Covishield may also induce muscle pain, generalized weakness, and fever, while Covaxin has been associated with tremors in certain specific cases. These side effects are typically minor and align with those observed in other vaccinations.
What’s next
As of May 2021, over 16.04 crore vaccinations have been administered in India, with 81% of recipients receiving their frist dose and 19% receiving the second.With a recovery rate of 82%, India has seen over 1.69 crore total recoveries.As research continues, there are currently 115 candidate vaccines, with 33 in Stage 3 clinical trials. Sputnik V has also been cleared for use in India, joining Covishield and Covaxin in the country’s vaccination efforts. Health officials have stated that both Covaxin and Covishield are effective against mutated strains of the virus.